Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Obama administration's $1 billion tax program at the very least signals a continued commitment to innovative biotech. The same cannot be said of plans afoot by the French government.
Claims of conflicts of interest concerning authorship of a scientific paper highlight the difficulties facing regulators participating in collaborations with industry.
High-throughput technologies are enabling epigenetic modifications to be mapped on a genome-wide scale, but whether such knowledge can be rapidly translated into biomedical applications remains unclear.
The US Food and Drug Administration (FDA) decision to approve a generic heparin derivative without clinical safety or efficacy data raises the possibility that clinical trials might not always be required for the approval of follow-on biologics.
With biotech infiltrating multiple industries and fewer life science ventures listing on stock exchanges, what do we really learn from surveying the set of public biotech companies?
The MAQC consortium's latest study suggests that human error in handling DNA microarray data analysis software could delay the technology's wider adoption in the clinic.
The sheer pace of discovery in genetics is placing companies that pursue an aggressive infringement strategy for gene patents increasingly at odds with innovation.
A consortium of industry, nonprofit institutions and regulators outlines a rolling biomarker qualification process, providing the first clear path for translation of such markers from discovery to preclinical and clinical practice.
Healthcare reform will not only boost biotech investment by massively expanding the US drug market, but also change the dynamics of biotech innovation in the longer term.